Jupiter Neurosciences Inc (NASDAQ: JUNS)’s stock price has soared by 23.18 in relation to previous closing price of 4.40. Nevertheless, the company has seen a loss of -34.86% in its stock price over the last five trading days. globenewswire.com reported 2024-12-04 that Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline targeting neuroinflammation with its unique resveratrol platform product, JOTROL™, today announced the closing of its initial public offering of 2,750,000 shares of common stock at a price of $4.00 per share for gross proceeds of $11 million, before deducting underwriting discounts and other related expenses.
Is It Worth Investing in Jupiter Neurosciences Inc (NASDAQ: JUNS) Right Now?
Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for JUNS is 14.11M, and currently, short sellers hold a 0.38% ratio of that float. The average trading volume of JUNS on January 22, 2025 was 558.34K shares.
JUNS’s Market Performance
The volatility ratio for the week is 31.37%, and the volatility levels for the last 30 days are 24.77% for Jupiter Neurosciences Inc (JUNS). The simple moving average for the past 20 days is -37.59% for JUNS’s stock, with a -39.91% simple moving average for the past 200 days.
JUNS Trading at -39.91% from the 50-Day Moving Average
After a stumble in the market that brought JUNS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.22% of loss for the given period.
Volatility was left at 24.77%, however, over the last 30 days, the volatility rate increased by 31.37%, as shares sank -51.78% for the moving average over the last 20 days.
During the last 5 trading sessions, JUNS fell by -34.86%, in comparison to the 20-day moving average, which settled at $8.68. In addition, Jupiter Neurosciences Inc saw -49.35% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for JUNS
The total capital return value is set at 0.39.
Based on Jupiter Neurosciences Inc (JUNS), the company’s capital structure generated -0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -0.51. The debt to equity ratio resting at -0.13. The interest coverage ratio of the stock is -7.49.
Currently, EBITDA for the company is -4.56 million with net debt to EBITDA at -0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.00.
Conclusion
To put it simply, Jupiter Neurosciences Inc (JUNS) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
